Reviewed by James Ives, M.Psych. (Editor)Jan 9 2019The U.S. Food and Drug Administration has accepted an Investigational New Drug application by physician-scientists at University of California San Diego School of Medicine to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy. The planned trial will be conducted in collaboration with AmpliPhi Biosciences Corporation, a San Diego-based biotechnology company.Bacteriophages, or phages, are viruses that specifically target and consume bacteria. They are ubiquitous, found wherever bacteria exist and were once considered a promising therapeutic tool. The advent of modern antibiotics in the 1930s redirected research interests, but with 10 million people estimated to die from drug-resistant “superbug” infections by 2050, they are getting a second look.In 2017, a multi-institution effort led by UC San Diego scientists (and including AmpliPhi) successfully used an unprecedented phage therapy in a last-ditch, emergency effort to save a colleague dying from a multi-resistant bacterium.That effort has been followed by a handful of singular cases, including the successful eradication of a years-long bacterial infection that allowed a patient to undergo a needed heart transplant.Encouraged by the progress, UC San Diego Chancellor Pradeep Khosla last year awarded a three-year, $1.2 million grant to launch the Center for Innovative Phage Applications and Therapeutics (IPATH) in the UC San Diego School of Medicine, the first such center in North America. The clinical trial will be IPATH’s first.The proposed Phase I/II clinical trial will test AB-SA01, an experimental bacteriophage combination for the treatment of participants with ventricular assist devices (VADs) infected by resistant Staphylococcus aureus (S. aureus). The trial will evaluate the safety, tolerability and efficacy of AB-SA01 bacteriophage therapy in combination with best available antibiotic therapies. There will be approximately 10 participants enrolled. They will be treated at UC San Diego Health and other leading teaching hospitals in the United States.Related StoriesCutting around 300 calories a day protects the heart even in svelte adultsNew methods to recognize antimicrobial resistant bacteria and how they workNANOLIVE‘s novel CX-A defines a new standard for live cell imaging in 96 well plates for continuous organelle monitoring in cell populationsVADs are implantable mechanical pumps that help pump blood in patients with weakened hearts or heart failure. They are sometimes used as a transitional device for patients awaiting a heart transplant.”There is a high, unmet need in patients with S. aureus VAD infections, which are typically very difficult to eradicate with conventional antibiotic therapy,” said the trial’s principal investigator, Saima Aslam, MD, associate professor of medicine and medical director of the Solid Organ Transplant Infectious Disease Service at UC San Diego Health.”In 2018, our UC San Diego Health team treated a patient with a S. aureus VAD infection using AB-SA01 under AmpliPhi’s Expanded Access Program. This clinical trial builds on that foundational work and could provide a much-needed and promising treatment option for this life-threatening condition.”Steffanie Strathdee, PhD, associate dean of global health sciences, Harold Simon Professor in the Department of Medicine and co-director of IPATH, said the planned trial is a natural progression from the first phage treatment at UC San Diego in 2017.It was her husband, Tom Patterson, PhD, a professor in the Department of Psychiatry, who had been stricken by a seemingly untreatable bacterial infection while vacationing in Egypt. By the time Patterson was airlifted back to Thornton Pavilion, part of Jacobs Medical Center at UC San Diego Health, he was seriously ill and would soon slip into a coma.”We’re excited to initiate IPATH’s first clinical trial,” said Strathdee. “And this is just the beginning. This collaboration is one of many we are undertaking to bring phage therapy into the 21st century to combat the global crisis of life-threatening antibiotic-resistant infections.” Source:https://health.ucsd.edu/news/releases/Pages/2019-01-08-FDA-okays-uc-san-diego-to-launch-novel-phage-study.aspx
Explore further About 20 minutes into trading, the Dow Jones Industrial Average down 0.1 percent at 26,409.49.The broad-based S&P 500 shed 0.2 percent to 2,909.67, while the tech-rich Nasdaq Composite Index declined 0.3 percent 8,019.29.Tesla was off about 11 percent at $273.60 following a bombshell announcement by the US Securities and Exchange Commission late Thursday that it was charging Musk for making “false and misleading” statements on Twitter on a now-aborted effort to take the electric car maker private.The SEC is seeking to bar Musk from serving as an officer of a publicly traded company.Analyst notes said the SEC’s move would likely increase the costs for Tesla to raise capital and could bolster private litigation against Tesla over Musk’s claims on going private, while the prospect of Musk’s complete removal was also worrisome.”We believe it is important for the confidence of investors that Mr. Musk remain involved,” said a note from JPMorgan Chase.”We believe that the perceived ‘magic’ and ‘mystique’ of Elon Musk on the part of a large contingent of investors is a key reason the stock has commanded the lofty valuation multiples it has in recent years,” the note added.A key US inflation measure, the Personal Consumption Expenditures price index, rose 2.2 percent in August, down from the 2.3 percent recorded for May, June and July. The respite from sustained price pressures follows the Federal Reserve’s decision this week to raise interest rates.US investors were also monitoring European bourses, where stocks fell sharply after Italy’s new government reached a deal on a much higher deficit, risking a big fight with Brussels. The US Securities and Exchange Commission has filed a lawsuit accusing Tesla’s Elon Musk of securities fraud Citation: Tesla shares plunge after US fraud suit against Musk (2018, September 28) retrieved 17 July 2019 from https://phys.org/news/2018-09-tesla-plunge-fraud-musk.html Tesla shares fall again on doubts about go-private deal Tesla shares plunged Friday in the first session since US securities regulators sued chief Elon Musk for fraud, with the company shedding more than 10 percent as US stocks retreated. © 2018 AFP This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
COMMENT NMPT will also construct toilets in two other areas, and the district administration and Mangaluru City Corporation have been asked to suggest those locations Considering the lack of good rest-rooms in places of tourist interest, New Mangalore Port Trust (NMPT) has decided to build four such facilities in two districts of coastal Karnataka.NMPT Chairman MT Krishna Babu said cruise vessels from different parts of the world call at the port regularly and tourists visit places of interest in Dakshina Kannada and Udupi districts. These visitors expect clean and aesthetically appealing facilities.Considering this, NMPT has initiated the process to improve toilet facilities near two temples — Kadri and Kudroli — in Mangaluru, near a Jain basadi in Moodbidri of Dakshina Kannada district, and near the Gomateshwara statue in Karkala taluk of Udupi district. The decision follows the feedback the port received from cruise tourists. Many tourists complained of lack of good rest-rooms at the places they visited, he said. The construction of these toilets will be taken up on a priority basis. Stating that these rest rooms will be maintained by NMPT, he said just construction of toilets and leaving their maintenance to the locals may not help. He made it clear that these toilets would not be limited just to the use of cruise tourists. The toilets are for all tourists visiting these areas and will be available round the clock. NMPT will also construct toilets in two other areas, and the district administration and Mangaluru City Corporation have been asked to suggest those locations. New Mangalore Port handled 24,258 passengers and 22 cruise vessels during the 2017-18 season. The traffic manager of NMPT had recently stated that the port is likely to handle 32 cruise vessels during the current season. The season concludes in May. SHARE January 28, 2019 Published on SHARE SHARE EMAIL COMMENTS
Train carrying water from Jolarpettai arrives in parched ChennaiThe train with 50 tank wagons (BTPN), carrying 50,000 litres of water in each of them from Jolarpettai in Tamil Nadu’s Vellore district, reached the filling station at the Integral Coach Factory in Villivakkam Friday afternoon.advertisement Press Trust of India ChennaiJuly 12, 2019UPDATED: July 12, 2019 14:15 IST Around 100 inlet pipes installed near the railway tracks would be used to discharge 2.5 million litres of water. (Photo: IANS)A train carrying 2.5 million litres of water arrived in Chennai, which has been grappling with an acute water crisis over the past few months, officials said Friday.The train with 50 tank wagons (BTPN), carrying 50,000 litres of water in each of them from Jolarpettai in Tamil Nadu’s Vellore district, reached the filling station at the Integral Coach Factory in Villivakkam Friday afternoon.Around 100 inlet pipes installed near the railway tracks would be used to discharge 2.5 million litres of water in all the wagons to be sent to a treatment plant after passing through a conduit, an official of Chennai Metropolitan Water Supply and Sewerage Board said.”After treatment it would be sent for distribution. This arrangement has been made for the next six months until the (advent of the) north-east monsoon,” the official told PTI.The train was supposed to reach Chennai on Thursday, but leakages in the valves led to the delay. Jolarpettai is 217 km away from the southern metropolis.All the arrangements took around 20 days of time to complete.The initiative would be formally inaugurated by Tamil Nadu Ministers later in the day, the official said.Chennai has been grappling with an acute water crisis over the past few months. The southern metropolis is facing a daily water deficit of at least 200 million litres, and the four reservoirs supplying to the city have run dry.The Tamil Nadu government had earlier requested the railways to help them ferry the water to the city.Earlier, Chief Minister K Palaniswami had announced mitigating Chennai’s water woes by getting drinking water supplied from Jolarpettai with an allocation of Rs 65 crore.ALSO READ | Water woes: Running out of time | India Today InsightALSO WATCH | Tamil Nadu remains on edge as state struggles to endure water crisisFor the latest World Cup news, live scores and fixtures for World Cup 2019, log on to indiatoday.in/sports. Like us on Facebook or follow us on Twitter for World Cup news, scores and updates.Get real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Posted bySnigdha Choudhury Next